Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.

[1]  Jinming Song,et al.  Adopting solutions for annotation and reporting of next generation sequencing in clinical practice , 2020, Practical laboratory medicine.

[2]  M. Pichichero,et al.  Panel 3: Genomics, precision medicine and targeted therapies. , 2019, International journal of pediatric otorhinolaryngology.

[3]  Romano Danesi,et al.  Precision Medicine in Lymphoma by Innovative Instrumental Platforms , 2019, Front. Oncol..

[4]  F. Rojo,et al.  Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology , 2019, Clinical and Translational Oncology.

[5]  A. Grumezescu,et al.  Magnetic Particles for Advanced Molecular Diagnosis , 2019, Materials.

[6]  N. Schultz,et al.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[8]  P. Hwu,et al.  Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study. , 2018, Journal of Clinical Oncology.

[9]  G. Otterson,et al.  Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. , 2018 .

[10]  Edward S. Kim,et al.  Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. , 2018 .

[11]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[12]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[13]  R. Shrestha,et al.  Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness , 2018, Clinical genetics.

[14]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[15]  J. Marshall,et al.  Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients , 2018, Cancer medicine.

[16]  S. Im,et al.  A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer , 2018, Clinical Cancer Research.

[17]  L. Miller,et al.  Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Thomas Wiegel,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[19]  V. Georgoulias,et al.  ESR1 Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment , 2017, Clinical Cancer Research.

[20]  S. Gallinger,et al.  Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. , 2017, Trends in molecular medicine.

[21]  N. Schultz,et al.  Clinical and molecular characterization of patients with cancer of unknown primary in the modern era , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Eshleman,et al.  Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. , 2017, JCO precision oncology.

[23]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[24]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[25]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[26]  Ruth Etzioni,et al.  Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[27]  Marina N Nikiforova,et al.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[28]  A. Bode,et al.  Precision medicine: the foundation of future cancer therapeutics , 2017, npj Precision Oncology.

[29]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[30]  Michael R. Speicher,et al.  Emerging concepts in liquid biopsies , 2017, BMC Medicine.

[31]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[32]  Daniel Durocher,et al.  The control of DNA repair by the cell cycle , 2016, Nature Cell Biology.

[33]  A. Sood,et al.  RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. , 2016, Cancer treatment reviews.

[34]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[35]  B. Han,et al.  ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  G. Hortobagyi,et al.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.

[37]  M. Dowsett,et al.  Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Yu Shyr,et al.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.

[39]  Ryan D. Morin,et al.  Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation , 2016, International journal of molecular sciences.

[40]  C Caldas,et al.  Consensus on precision medicine for metastatic cancers: a report from the MAP conference. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  S. Loi,et al.  Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). , 2016 .

[42]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[43]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[44]  Stefanie S Jeffrey,et al.  Circulating tumor cell technologies , 2016, Molecular oncology.

[45]  M. Dowsett,et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.

[46]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[47]  J. D. Watson,et al.  Human Genome Project: Twenty-five years of big biology , 2015, Nature.

[48]  Jorge S. Reis-Filho,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[49]  Daniel F. Hayes,et al.  ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients , 2015, Clinical Cancer Research.

[50]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[52]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[53]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[54]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[55]  H. Nielsen,et al.  Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.

[56]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[57]  S. Dawson,et al.  Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  K. Griffith,et al.  Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.

[59]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[60]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[62]  Benjamin J. Raphael,et al.  Expanding the computational toolbox for mining cancer genomes , 2014, Nature Reviews Genetics.

[63]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[64]  Aviv Regev,et al.  Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer , 2014, Nature Biotechnology.

[65]  Benjamin J. Raphael,et al.  Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine , 2014, Genome Medicine.

[66]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[67]  James X. Sun,et al.  Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.

[68]  R. Yelensky,et al.  D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. , 2013, Cancer research.

[69]  K. Pantel,et al.  Imaging , Diagnosis , Prognosis PrognosticRelevanceofCirculatingTumorCells inBloodand Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity , 2013 .

[70]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[71]  K. Pantel,et al.  Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma , 2013, International journal of cancer.

[72]  Rodney Rothstein,et al.  Repair of strand breaks by homologous recombination. , 2013, Cold Spring Harbor perspectives in biology.

[73]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.

[74]  A. Howell,et al.  Edinburgh Research Explorer Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 random , 2013 .

[75]  H. Soares,et al.  Non-Coding RNAs: Multi-Tasking Molecules in the Cell , 2013, International journal of molecular sciences.

[76]  Gary D Bader,et al.  Computational approaches to identify functional genetic variants in cancer genomes , 2013, Nature Methods.

[77]  M. Ychou,et al.  Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. , 2013, Translational Oncology.

[78]  Peter Ulz,et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.

[79]  S. Miyano,et al.  Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. , 2013, Cancer research.

[80]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[81]  J. Hainsworth,et al.  Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[83]  S. Kimura,et al.  Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[84]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[85]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[86]  S. Minner,et al.  Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. , 2012, European urology.

[87]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[88]  Christophe Massard,et al.  Carcinomas of an unknown primary origin—diagnosis and treatment , 2011, Nature Reviews Clinical Oncology.

[89]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[90]  T. Fehm,et al.  HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.

[91]  N. Pavlidis,et al.  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  S. Gruber,et al.  Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.

[93]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[94]  P. Jänne,et al.  Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[95]  R. Lister,et al.  Highly Integrated Single-Base Resolution Maps of the Epigenome in Arabidopsis , 2008, Cell.

[96]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[97]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[98]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[99]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[100]  A. Ullrich,et al.  Beyond Herceptin and Gleevec. , 2003, Current opinion in chemical biology.

[101]  Mark Rothmann,et al.  Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  J. R. Morris,et al.  Genes, genetics, and epigenetics: a correspondence. , 2001, Science.

[103]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[104]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[105]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[106]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[107]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[108]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[109]  C. Boland,et al.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. , 1993, Gastroenterology.

[110]  Jack W. Szostak,et al.  The double-strand-break repair model for recombination , 1983, Cell.

[111]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[112]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[113]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[114]  Dede Sika Kossi,et al.  Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study , 2017, European Journal of Human Genetics.

[115]  C. Bokemeyer,et al.  Circulating tumor cells in patients with testicular germ cell tumors. , 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.